AIM ImmunoTech (NYSE:AIM) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.
Valuation & Earnings
This table compares AIM ImmunoTech and CASI Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AIM ImmunoTech||$140,000.00||494.08||-$9.53 million||N/A||N/A|
|CASI Pharmaceuticals||$4.13 million||65.73||-$46.03 million||($0.42)||-6.40|
AIM ImmunoTech has higher earnings, but lower revenue than CASI Pharmaceuticals.
This table compares AIM ImmunoTech and CASI Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
2.1% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 20.2% of CASI Pharmaceuticals shares are held by institutional investors. 15.0% of AIM ImmunoTech shares are held by company insiders. Comparatively, 24.3% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
AIM ImmunoTech has a beta of -1.05, suggesting that its share price is 205% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
This is a summary of current ratings for AIM ImmunoTech and CASI Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AIM ImmunoTech presently has a consensus target price of $4.50, suggesting a potential upside of 89.87%. CASI Pharmaceuticals has a consensus target price of $3.50, suggesting a potential upside of 30.11%. Given AIM ImmunoTech’s higher possible upside, equities analysts clearly believe AIM ImmunoTech is more favorable than CASI Pharmaceuticals.
CASI Pharmaceuticals beats AIM ImmunoTech on 7 of the 11 factors compared between the two stocks.
AIM ImmunoTech Company Profile
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.